JSM 2012 Home

JSM 2012 Online Program

The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.

Online Program Home

Abstract Details

Activity Number: 515
Type: Contributed
Date/Time: Wednesday, August 1, 2012 : 10:30 AM to 12:20 PM
Sponsor: Biopharmaceutical Section
Abstract - #305415
Title: Changes in Tumor Size as a Continuous Variable in Phase II Trials Rather Than WHO/RECIST Response to Improve Success Rate of Confirmatory Phase III Trials
Author(s): Zhengjia Chen*+ and Sungjin Kim and Taofeek K Owonikoko and Zhibo Wang and Suresh S Ramalingam and Dong M Shin and Fadlo R Khuri and Jeanne Kowalski
Companies: Biostatistics and Bioinformatics Shared Resource at Winship Cancer Institute and Winship Cancer Institute and Emory University and Winship Cancer Institute and Emory University and Emory University and Emory University and Biostatistics and Bioinformatics Shared Resource at Winship Cancer Institute
Address: 1365B Clifton Road, Atlanta, GA, 30322,
Keywords: Tumor response ; World Health Organization (WHO) ; and Response Evaluation Criteria In Solid Tumors (RECIST) ; Percent tumor change ; Efficacy ; Success rate of Phase III trials

In Phase II cancer clinical trials, tumor response is widely used as a surrogate for clinical benefit and overall survival. The change in tumor size, a continuous variable, is typically transformed into a categorical variable (complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD)) according to two well-established and widely employed criteria: WHO and RECIST. It is generally assumed that patient's survival chance increases with the magnitude of tumor response i.e. CR>PR>SD>PD. But from statistical consideration, this approach results in loss of study power by not fully utilizing all available data. We employed survival as a gold standard to compare the powers to accurately establish treatment efficacy between two approaches: a continuous endpoint (tumor percent change) and its categorical endpoint (tumor response according to WHO/RECIST). Simulation studies and real data from a completed Phase II trial show that the continuous endpoint achieved a higher power to identify a treatment agent likely to achieve significantly improved survival, thus resulting in substantial improvement in trial efficiency and success rate of Phase III clinical trial

The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.

Back to the full JSM 2012 program

2012 JSM Online Program Home

For information, contact jsm@amstat.org or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.